Dr. Coleman’s research interests include novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, surgical innovations and graduate education. In partnership with Departmental faculty, he has established a translational medicine pipeline, which fosters, facilitates and vets promising compounds and treatment strategies from preclinical to clinical investigation. He is the institution’s Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, as well as, numerous investigator-initiated clinical studies of novel chemotherapeutic and biological compounds in cancers of the ovary, cervix and uterus. He has also been involved in three trials evaluating lymphatic mapping for gynecologic malignancies. He currently is a co-Project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, The Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. In addition, recent funding from the Cancer Prevention Research Institute of Texas (CPRIT) will be used to support a first-in-human therapeutics study of systemically delivered siRNAs in patients with solid tumors.
In June 2010 he was appointed to the Ann Rife Cox Chair in Gynecology and is a member of the M.D. Anderson Cancer Center's Center for RNA Interference and Non-Coding RNA.